10-Q/A: Paragon 28 Restates Q1 2024 Financials Due to Inventory Errors

Paragon 28 has restated its first quarter 2024 financial statements due to material accounting errors related to inventory valuation.

Summary

• Paragon 28 has filed an amended quarterly report to restate its financials for the three months ended March 31, 2024.
• The restatement was necessary due to errors in the calculation of excess and obsolete inventory, as well as accounting for inventory variances.
• These errors led to an overstatement of inventory and an understatement of cost of goods sold in previous reports.
• The company has corrected these errors, along with other immaterial accounting and disclosure errors.
• The amended report includes restated financial statements and related notes.
• The company's net revenue for the quarter was $61.1 million, a 17% increase compared to the same period last year.
• Gross profit margin decreased to 77.3% from 80.3% in the prior year due to increased supplier costs and inventory adjustments.
• The company reported a net loss of $17.4 million for the quarter.
• Adjusted EBITDA was negative $7.7 million, compared to negative $2.7 million in the same period last year.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the restatement of financials, material weaknesses in internal controls, decreased gross profit margin, and a net loss. While revenue growth is positive, the underlying issues raise significant concerns.

Positives

• Net revenue increased by 17% year-over-year, reaching $61.1 million.
• International revenue grew by 42% compared to the prior year, driven by the United Kingdom and Australia.
• The company is actively investing in new product development.

Negatives

• The company had to restate its financial statements due to material accounting errors.
• Gross profit margin decreased to 77.3% from 80.3% in the prior year.
• The company reported a net loss of $17.4 million for the quarter.
• Adjusted EBITDA was negative $7.7 million, a decrease compared to the prior year.
• Material weaknesses were identified in the company's internal control over financial reporting.

Risks

• The company's internal controls over financial reporting were found to have material weaknesses.
• The company's remediation plan may not be successful in addressing these weaknesses.
• The company's future financial results may be negatively impacted by the identified accounting errors.
• The company's gross profit margin is under pressure due to increased supplier costs and inventory adjustments.
• The company's international expansion may be subject to fluctuations in foreign currency exchange rates.

Future Outlook

The company expects net revenue to increase as they expand sales territories, add new customers, and increase product utilization. They also expect research and development and selling, general, and administrative expenses to increase as they grow their business.

Management Comments

• Management is devoting significant time, attention, and resources to remediate the material weaknesses and to strengthen its monitoring, control environment, and internal control over financial reporting.
• Management believes that the measures described above and others that may be implemented will remediate the identified material weaknesses and strengthen the Company's internal control over financial reporting.

Industry Context

The company operates in the competitive and rapidly changing medical device industry, specifically within the foot and ankle orthopedic market. The restatement highlights the importance of accurate inventory management and financial reporting in this sector.

Comparison to Industry Standards

• While the document does not provide specific comparisons to industry standards, the restatement of financials due to inventory errors is a significant issue that would likely be viewed negatively by investors and compared to peers who have not had similar issues.
• Companies like Stryker, Zimmer Biomet, and Medtronic, which are major players in the broader orthopedic market, are expected to have robust internal controls and accurate financial reporting. Paragon 28's restatement would be seen as a deviation from these standards.
• The company's gross margin of 77.3% is within the range of medical device companies, but the decrease from 80.3% is a concern that would be compared to peers.
• The negative Adjusted EBITDA of $7.7 million would be compared to the profitability metrics of other companies in the medical device space.

Management Changes

Legal Proceedings

• As of March 31, 2024, the Company is not involved in any legal proceedings that could have a material adverse effect on its condensed consolidated financial position.

Related Party Transactions

• The company has a license agreement with an entity affiliated with one of its directors, under which it pays a royalty of 4% of net revenue related to the licensed intellectual property, with a minimum annual payment of $250.

Stakeholder Impact

• Shareholders will be negatively impacted by the restatement and the identified material weaknesses in internal controls.
• Employees may be impacted by the changes in the organizational structure and reporting structure of the controllership function.
• Customers may be impacted by any potential disruptions in the company's operations.
• Suppliers may be impacted by any changes in the company's purchasing practices.
• Creditors may be impacted by the company's financial performance and ability to meet its obligations.

Next Steps

• The company plans to continue to devote significant time and attention to remediate the material weaknesses in internal controls.
• The company will continue to invest in new product development.
• The company will continue commercialization efforts and expand its sales and marketing infrastructure.

Key Dates

Keywords

restatement, inventory, financial results, accounting errors, internal controls, net revenue, gross profit, EBITDA, medical devices, orthopedic, foot and ankle